Loading…
Loading…
GNLX does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for GNLX and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for GNLX and 80,000+ other tickers.
See exactly how GNLX's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for GNLX and 80,000+ other tickers.
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.
-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Olvi-Vec systemic development programs continue to advance, with additional dose-escalation updates anticipated in 2026 --
Genelux (NASDAQ: GNLX - Get Free Report) is expected to post its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter. Parties can check the company's upcoming Q2 2026 earning overview page for the latest details on the call scheduled
- Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from Phase 2 VIRO-15 trial -
-- Topline data from randomized Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Systemic lung cancer programs advancing with additional updates expected throughout 2026 -- -- $26.3 million in cash, cash equivalents, marketable securities and restricted cash as of March 31, 2026; expected to fund operations into 1Q27 -- WESTLAKE VILLAGE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2026 and provided general business updates.
-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses in relapsed small cell lung cancer (SCLC) and early signs of anti-tumor activity in non-small cell lung cancer (NSCLC); additional updates expected throughout 2026 --